Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists Reply

To the Editor: The distribution framework for glucagon-like peptide-1 (GLP-1) receptor agonists proposed by Emanuel et al. in their Perspective article (May 30 issue)(1) considers potential years of life lost (PYLL) from obesity-related disease, but not race. How can clinicians and policymakers implement this framework "irrespective of factors such as race" (Table 1 in the article) when race and ethnic group are strongly associated with both PYLL and the risk of obesity-related disease? The PYLL metric - life expectancy minus the age at which a person dies - is seldom used in clinical medicine. But PYLL and life expectancy are . . .